Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients
31 août 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the...
U.S. Patent and Trademark Office Awards Nuwellis Patent for Innovative Pediatric Technology
25 août 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a commercial stage company dedicated to transforming the lives of patients suffering from fluid overload, today announced...
Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
19 août 2022 15h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective August 18, 2022, the independent directors approved equity awards under Nuwellis’ 2021...
Nuwellis Inc. to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
19 août 2022 08h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase,...
Nuwellis, Inc. Announces Second Quarter 2022 Financial Results
09 août 2022 08h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2022, which included the following highlights: ...
Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA
26 juil. 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced the...
Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022
14 juil. 2022 08h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022. The company...
Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy
12 juil. 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key...
Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF
29 juin 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the company’s pivotal REVERSE-HF (Ultrafiltration Versus IV...
Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas
14 juin 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, June 14, 2022 (GLOBE NEWSWIRE) -- Improving access to life-saving fluid management therapies is a commitment by which Nuwellis, Inc. (Nasdaq: NUWE) stands. The company today announced...